Related Experiment Videos
Failure of penicillin to eradicate the carrier state of group B Streptococcus in infants
Abstract:
Serial cultures were obtained from 12 patients being treated with a form of penicillin for group B streptococcal disease or asymptomatic colonization. These cultures were collected prior to initiation of therapy, during therapy, and at the end of the treatment period. Pencillin eradicated GBS from the involved system (blood, CSF, bone, and joint). Cultures remained positive from at least one of three carrier sites (throat, umbilicus, and rectum) in 70% of patients cultured between days one and eight of treatment and 66% between days 10 and 21. These data demonstrate the failure of penicillin to eradicate GBS from mucous surfaces of young infants.
Insights
Penicillin effectively eradicated Group B Streptococcus (GBS) from infant infections but failed to clear the bacteria from carrier sites like the throat and rectum. This highlights a significant limitation in treating GBS colonization.
Area of Science:
- Infectious Diseases
- Neonatal Medicine
- Microbiology
Background:
- Group B Streptococcus (GBS) is a significant cause of neonatal infections.
- Penicillin is a primary antibiotic used for treating GBS disease and colonization.
- Understanding GBS eradication from various body sites is crucial for effective treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of penicillin in eradicating Group B Streptococcus (GBS) from both systemic infections and mucosal carrier sites in infants.
- To determine the persistence of GBS in carrier sites during and after penicillin therapy.
Main Methods:
- Serial cultures were collected from 12 patients receiving penicillin for GBS disease or colonization.
- Cultures were obtained before, during, and after the treatment period.
- Sampling included systemic sites (blood, CSF, bone, joint) and mucosal carrier sites (throat, umbilicus, rectum).
Main Results:
- Penicillin successfully eradicated GBS from systemic sites such as blood, cerebrospinal fluid (CSF), bone, and joint.
- GBS persisted in at least one carrier site (throat, umbilicus, rectum) in 70% of patients during days 1-8 of treatment.
- Persistence was observed in 66% of patients between days 10 and 21 of treatment.
Conclusions:
- Penicillin therapy is effective in clearing GBS from invasive infections in infants.
- Penicillin demonstrates limited efficacy in eradicating GBS from mucosal surfaces, indicating persistent colonization.
- These findings underscore the challenge of completely eliminating GBS carriage with penicillin in young infants.